» Articles » PMID: 33865797

Limited Versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial

Overview
Journal Eur Urol Oncol
Specialties Oncology
Urology
Date 2021 Apr 18
PMID 33865797
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pelvic lymph node dissection (PLND) is the most reliable procedure for lymph node staging. However, the therapeutic benefit remains unproven; although most radical prostatectomies at academic centers are accompanied by PLND, there is no consensus regarding the optimal anatomical extent of PLND.

Objective: To evaluate whether extended PLND results in a lower biochemical recurrence rate.

Design, Setting, And Participants: We conducted a single-center randomized trial. Patients, enrolled between October 2011 and March 2017, were scheduled to undergo radical prostatectomy and PLND. Patients were assigned to limited or extended PLND by cluster randomization. Specifically, surgeons were randomized to perform limited or extended PLND for 3-mo periods.

Intervention: Randomization to limited (external iliac nodes) or extended (external iliac, obturator fossa and hypogastric nodes) PLND.

Outcome Measurements And Statistical Analysis: The primary endpoint was the rate of biochemical recurrence.

Results And Limitations: Of 1440 patients included in the final analysis, 700 were randomized to limited PLND and 740 to extended PLND. The median number of nodes retrieved was 12 (interquartile range [IQR] 8-17) for limited PLND and 14 (IQR 10-20) extended PLND; the corresponding rate of positive nodes was 12% and 14% (difference -1.9%, 95% confidence interval [CI] -5.4% to 1.5%; p = 0.3). With median follow-up of 3.1 yr, there was no significant difference in the rate of biochemical recurrence between the groups (hazard ratio 1.04, 95% CI 0.93-1.15; p = 0.5). Rates for grade 2 and 3 complications were similar at 7.3% for limited versus 6.4% for extended PLND; there were no grade 4 or 5 complications.

Conclusions: Extended PLND did not improve freedom from biochemical recurrence over limited PLND for men with clinically localized prostate cancer. However, there were smaller than expected differences in nodal count and the rate of positive nodes between the two templates. A randomized trial comparing PLND to no node dissection is warranted.

Patient Summary: In this clinical trial we did not find a difference in the rate of biochemical recurrence of prostate cancer between limited and extended dissection of lymph nodes in the pelvis. This study is registered on ClinicalTrials.gov as NCT01407263.

Citing Articles

Metastatic lymph nodes outside the extended lymphadenectomy template correlate with advanced staging but not grading in prostate cancer patients undergoing radical prostatectomy.

Karwacki J, Mioskowska A, Tomecka P, Maczka K, Gurwin A, Kobylanski M Int Urol Nephrol. 2025; .

PMID: 40088356 DOI: 10.1007/s11255-025-04450-0.


Diagnostic Accuracy of Indocyanine Green-stained Sentinel Lymph Nodes in Prostate Cancer Patients: A Systematic Review and Meta-analysis.

Chou Y, Chang C, Tsai Y Eur Urol Open Sci. 2025; 74:34-43.

PMID: 40066190 PMC: 11891741. DOI: 10.1016/j.euros.2025.02.002.


Impact of peritoneal bladder flap in robot-assisted radical prostatectomy patients on lymphoceles: a prospective randomised trial.

Pose R, Knipper S, Beyer B, Hohenhorst L, Haese A, Heinzer H World J Urol. 2025; 43(1):148.

PMID: 40044802 DOI: 10.1007/s00345-025-05518-3.


Extended Lymph Node Dissection May Not Provide a Therapeutic Benefit in Patients with Intermediate-to High-Risk Prostate Cancer Treated with Robotic-Assisted Radical Prostatectomy.

Miura N, Shimbo M, Okawa D, Sakamoto M, Sugihara N, Sawada T Cancers (Basel). 2025; 17(4).

PMID: 40002250 PMC: 11853644. DOI: 10.3390/cancers17040655.


Comparison of oncological outcomes between extended and no pelvic lymph node dissection in patients with high- or very high-risk prostate cancer: a multi-institutional study.

Washino S, Kawase M, Shimbo M, Yamasaki T, Ohba K, Miki J Prostate Int. 2025; 12(3):160-166.

PMID: 39816941 PMC: 11733760. DOI: 10.1016/j.prnil.2024.07.002.


References
1.
Blencowe N, Mills N, Cook J, Donovan J, Rogers C, Whiting P . Standardizing and monitoring the delivery of surgical interventions in randomized clinical trials. Br J Surg. 2016; 103(10):1377-84. PMC: 5132147. DOI: 10.1002/bjs.10254. View

2.
Sanda M, Cadeddu J, Kirkby E, Chen R, Crispino T, Fontanarosa J . Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. J Urol. 2018; 199(4):990-997. DOI: 10.1016/j.juro.2018.01.002. View

3.
Bishoff J, Reyes A, Thompson I, Harris M, St Clair S, Gomella L . Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology. 1995; 45(2):270-4. DOI: 10.1016/0090-4295(95)80017-4. View

4.
de Boer A, van Lanschot J, van Sandick J, Hulscher J, Stalmeier P, de Haes J . Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus. J Clin Oncol. 2004; 22(20):4202-8. DOI: 10.1200/JCO.2004.11.102. View

5.
Riall T, Cameron J, Lillemoe K, Campbell K, Sauter P, Coleman J . Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival. J Gastrointest Surg. 2005; 9(9):1191-204. DOI: 10.1016/j.gassur.2005.08.034. View